U.S. FDA approves EPKINLY® for treating relapsed/refractory follicular lymphoma, first T-cell engaging bispecific antibody.
The U.S. FDA approves EPKINLY® (epcoritamab-bysp) for treating adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. It is the first and only T-cell engaging bispecific antibody approved in the U.S. for both R/R FL and R/R diffuse large B-cell lymphoma, administered subcutaneously. The approval is based on Phase 1/2 EPCORE® NHL-1 study results.
June 26, 2024
4 Articles